Stock Analiz

Arvinas, Inc. ARVN

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$6.82Market cap $447M
Open the interactive analysis →

Arvinas, Inc. (ARVN) is a healthcare company listed in the US with a market value of about $447M. In the twelve months to September 30, 2026 it had revenue of $275M and net income of -$10M, a net margin of -3.5%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 59% a year, a 5-year average ROIC of -33%.

About Arvinas

Arvinas is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $8M in 2017 to $263M in 2025, growth of about 55.8% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 33% over three years (dilution for shareholders). It spends 109% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.6
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-35.8%
Shareholder yield20.6%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-0.3%
Revenue growth (5 yrs, per year)58.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-229.1%
ROIC (5-yr avg.)-32.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$275M$263M$263M$78M$131M$54M$26M$43M$14M$8M
Net income-$10M-$81M-$199M-$367M-$282M-$191M-$119M-$70M-$41M-$24M
Free cash flow-$160M-$276M-$261M-$351M-$280M$555M-$96M-$47M-$19M$4M
EPS (diluted)$-0.10$-1.14$-2.77$-6.62$-5.31$-3.82$-3.02$-2.13$-25.45$-15.08
Net margin-3.5%-30.8%-75.5%-467.9%-215.0%-356.3%-460.6%-163.5%-289.6%-317.3%
ROIC—-21.1%-34.6%-47.8%-36.4%-23.9%-18.7%-17.6%-24.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 13 analysts is $14.00, 105% above the current price; targets range from $8.00 to $21.00; the consensus rating is “Buy”; expected EPS is $0.16 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Arvinas pay a dividend?

Not currently.

Is Arvinas a good stock to buy?

We do not give buy or sell advice. Arvinas scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.